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CLINICAL EFFICACY
Heat-related degradation of oxytocin is well-documented, 4 and studies in both Africa 5 and South Asia 6 have found a significant proportion of oxytocin sold at retail level falling outside of manufacturer specifications. The greater heat stability of carbetocin means there is more certainty about the actual delivered dose than there is for oxytocin. But this doesn't necessarily translate into any significant difference in clinical efficacy. In the new study, the authors claim oxytocin has "unsatisfactory real-world efficacy as a result of sensitivity to heat." 1 However, the evidence they cite consists only of assays of the amount of active pharmaceutical ingredient in the vials sampled, 7 not effects on patient outcomes. A recently published trial 8 provides good evidence that route of administration matters; in a doubleblinded, head-to-head comparison of oxytocin 10 IU administered intravenously versus intramuscularly, the investigators found significant differences in clinically important endpoints, with better results for intravenous administration than for intramuscular for blood loss ≥1000 cc (adjusted odds ratio [ From these trial results, it is certainly fair to say that evidence for clinical efficacy is better for 10 IU than for 5 IU (and that evidence for effectiveness of intramuscular administration of oxytocin 5 IU is particularly weak) * ; it would not be fair to say the evidence is definitive.
SAFETY
In addition to efficacy, an important consideration for uterotonics is safety, particular when used for labor augmentation. In many parts of the world, oxytocin (and sometimes other uterotonics) is commonly used for a Editor-in-Chief, Global Health: Science and Practice Journal, and Associate Professor, School of Public Health, University of Alberta, Edmonton, Alberta, Canada. Correspondence to Steve Hodgins (shodgins@ghspjournal.org).
*The Abdel-Aleem trial, 13 with a total sample of 1,950, provides robust evidence of clinical benefit of 10 IU administered intramuscularly. The only 2 studies using 5 IU administered intramuscularly were De Groot 10 and Poueschmann, 11 both of which were very small and therefore lacking in adequate statistical power for our clinical endpoints of interest. As a result, they provide little evidence one way or the other about clinical efficacy of 5 IU administered intramuscularly.
augmentation under unsafe conditions (not reliably ruling out mechanical obstruction, administering the drug intramuscularly or by intravenous bolus, failing to closely monitor the laboring woman, and not having timely access to emergency cesarean delivery). Because of dangers associated with uterotonic use during labor, oxytocin is designated as a high-alert medication. 15 Wide use under unsafe conditions makes an important contribution to poor birth outcomes in South Asia [16] [17] [18] [19] [20] and elsewhere. 21 Carbetocin would certainly be no safer in this respect. Given its considerably longer half-life, arguably, deploying it widely in place of oxytocin could increase risk of adverse outcomes related to such inappropriate use-notably fetal asphyxia and uterine rupture.
ACCESS
Oxytocin is an inexpensive medication; the median bulk price documented in the International Medical Products Price Guide from Management Sciences for Health is US$0.17 for a 10 IU amp 22 ; the price for oxytocin that the United Nations Population Fund currently has posted on its website is US$0.28 per amp. 23 And oxytocin is widely available and produced by many generic pharmaceutical manufacturers, although there are relatively few selling to low-and middle-income country markets that meet current global good manufacturing practices quality standards for oxytocin. For carbetocin to be a viable alternative to oxytocin, it would need to be similarly inexpensive and ubiquitous. It is reassuring to read that Ferring Pharmaceuticals, the sole supplier of carbetocin, hopes to make it "available in public-sector facilities of high-burden countries at an affordable and sustainable price," 1 but we're not there yet.
A QUIVER OF UTEROTONICS
Carbetocin is one of a suite of medicines that act on the myometrium and that, together, constitute an important set of tools for achieving better birth outcomes. It may be that carbetocin will eventually partially replace the use of some of the others for certain indications, in certain circumstances. But there will continue to be a need for oxytocin, misoprostol, tranexamic acid, and ergot alkyloids. Optimal strategies for how best to use this complement of drugs will vary by setting and need to take into account characteristics of the drugs, available evidence on effectiveness and safety, and the situation on the ground. 
